Finance Watch: IPOs At A Standstill As US Biotech Stock Valuations Plummet
First Three Major Launches Of The Year Holding Steady
There have been no biopharma initial public offerings in the US since 12 January while the industry’s valuations have plummeted by double digits since the start of 2022. Nevertheless, venture capital investment continues at a fast pace and there have been some follow-on public offerings.
